Literature DB >> 14667206

Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor.

John Kuruvilla1, Heather A Leitch, Linda M Vickars, Paul F Galbraith, Charles H Li, Saad Al-Saab, Sheldon C Naiman.   

Abstract

Upregulation of tumor necrosis factor-alpha (TNF-alpha) has been implicated in the pathogenesis of several inflammatory conditions, including rheumatoid arthritis. Therapeutic agents such as antibodies or soluble TNF-alpha receptor analogs, which block TNF-alpha activity are a recent addition to the therapeutic armamentarium for the conditions. We describe a patient who developed aplastic anemia complicated by sepsis after receiving etanercept, a TNF-alpha receptor analog, for the treatment of rheumatoid arthritis. Pancytopenia resolved within 3 wk of discontinuing etanercept. To our knowledge, this is the first report of aplastic anemia associated with TNF-alpha blockade.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14667206     DOI： 10.1034/j.1600-0609.2003.00115.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


  11 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.

Authors:  S Rajakulendran; K Gadsby; D Allen; S O'Reilly; C Deighton
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

3.  Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in mice.

Authors:  Junping Xin; Peter Breslin; Wei Wei; Jing Li; Rafael Gutierrez; Joseph Cannova; Allen Ni; Grace Ng; Rachel Schmidt; Haiyan Chen; Vamsi Parini; Paul C Kuo; Ameet R Kini; Patrick Stiff; Jiang Zhu; Jiwang Zhang
Journal:  Haematologica       Date:  2016-09-15       Impact factor: 9.941

Review 4.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

5.  TNF-alpha regulates the effects of irradiation in the mouse bone marrow microenvironment.

Authors:  Ana Sofia Cachaço; Tânia Carvalho; Ana Cristina Santos; Cátia Igreja; Rita Fragoso; Catarina Osório; Manuela Ferreira; Jacinta Serpa; Sofia Correia; Perpétua Pinto-do-O; Sérgio Dias
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

Review 6.  Ustekinumab: a new option in psoriasis therapy.

Authors:  Anna L Chien; James T Elder; Charles N Ellis
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

7.  Macrophage TNF-α licenses donor T cells in murine bone marrow failure and can be implicated in human aplastic anemia.

Authors:  Wanling Sun; Zhijie Wu; Zenghua Lin; Maile Hollinger; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

Review 8.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

9.  The relationship between blood eosinophil count and disease activity in ankylosing spondylitis patients treated with TNF-α inhibitors.

Authors:  Gokhan Sargin; Taskin Senturk; Irfan Yavasoglu
Journal:  Saudi Pharm J       Date:  2018-05-04       Impact factor: 4.330

Review 10.  Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms.

Authors:  Natasha Kozak; Joshua Friedman; Ami Schattner
Journal:  Drugs R D       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.